Heart disease Circulatory System Chronic ischaemic heart disease
Conditions
Interventions
1. Folate 5 mg
2. Placebo
Sponsors
NHS R&D Regional Programme Register - Department of Health (UK)
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients admitted for coronary angiograph 2. Stable angina 3. Positive coronary angiogram
Exclusion criteria
Exclusion criteria: Patients with a macrocytic anaemia (Hb 100) will be excluded from the pilot unless their serum B12 is normal. To be revised if indicated by follow-up results of Hb and B12 pilot.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Main Study 1.1. Fatal or non-fatal myocardial infarction. 2. Pilot Study 2.1. Percentage of patients with B12 deficiency on entry despite normal Hb and MCV, and patients becoming B12 deficient at follow-ups. 2.2. Percentage change in plasma homocysteine and plasma tetrahydrobiopterin in response to folic acid, and variation in these over one year. 2.3. Compliance with treatment addeddes from rise in rbc folate in active group. 2.4. Estimate of number of eligible patients likely to be recruited annually. | — |
Secondary
| Measure | Time frame |
|---|---|
| Not provided at time of registration | — |
Countries
United Kingdom
Outcome results
None listed